Journal of Clinical Oncology
Articles in this Issue
Estimating the clinical and economic impact of delaying recurrence in resectable gastric and gastroesophageal junction cancer in the United States.
295 Background: In the MATTERHORN trial, perioperative treatment with durvalumab + FLOT (D-FLOT) demonstrated a statistica...
Prognostic impact of <i>RAS/BRAF</i> mutations and clinical factors in 441 patients undergoing pulmonary metastasectomy for colorectal cancer.
214 Background: Pulmonary metastasectomy (PM) is a curative treatment option for colorectal cancer (CRC) patients with lun...
Advanced pancreatic adenocarcinoma outcomes in patients with DDR deficiencies outside of BRCA1/2 and PALB2.
759 Background: Pancreatic adenocarcinomas (PDAC) harboring deficiencies in BRCA1/2...
Multicenter prospective validation of PanClaudinAI: An AI for predicting Claudin 18.2 from CT in pancreatic cancer.
751 Background: Claudin 18.2 (CLDN18.2) is a promising therapeutic target in pancreatic cancer. Current immunohistochemist...
Survival outcomes in localized pancreatic cancer treated with neoadjuvant chemotherapy (NAC).
683 Background: There is uncertainty about whether chemotherapy administered perioperatively or only in the adjuvant setti...
Longitudinal morphomics and metabolomics as metastatic pancreatic cancer prognosticators.
781 Background: Morphomics evaluates patients’ body composition, including subcutaneous fat, visceral fat, muscle, and fas...
Comparative genomic profiles of <i>ERBB2/HER2</i> -mutant and -amplified colorectal cancers: A comprehensive cohort study.
210 Background: ERBB2/HER2 amplification defines a rare but clinically distinct subtype of colorectal...
A phase Ib/II, dose escalation and dose expansion study of valemetostat tosylate (DS-3201b) with atezolizumab and bevacizumab in advanced hepatocellular carcinoma (HCC).
TPS613 Background: Enhancer of zeste homolog 2 (EZH2) is overexpressed in HCC and correlates with poor prognosis. Preclini...
A phase 1, first-in-human, multicenter study of ZW251, a novel glypican-3 (GPC3)–targeted antibody-drug conjugate (ADC), in participants with hepatocellular carcinoma (HCC).
TPS608 Background: GPC3 is highly expressed in HCC and in select solid tumors, with limited expression in normal tissues,...
Impact of palliative care and acute care use at the end of life in young adults with GI cancers.
829 Background: Gastrointestinal (GI) cancer accounts for nearly 20% of all cancer cases in the United States. The inciden...
Neuroendocrine carcinoma of the esophagus: A genomic landscape study.
642 Background: Esophageal neuroendocrine carcinoma (ENEC) is a rare and aggressive upper GI tract malignancy when compare...
Preoperative chemotherapy with docetaxel, oxaliplatin, and S-1 for gastric cancer with extensive lymph node metastasis: 3-year follow-up results of JCOG1704.
396 Background: The prognosis for marginally resectable gastric cancer with extensive lymph node metastasis (ELM) remains...
Small cell carcinoma and large cell neuroendocrine carcinoma of colon and rectum: Incidence, survival outcomes, and comparison with well-differentiated neuroendocrine tumors (NETs) and adenocarcinoma.
622 Background: Colorectal small and large cell neuroendocrine carcinoma (SCNEC and LCNEC) comprise <1% of colorectal c...
Impact of hepatic arterial infusion pump (HAIP) therapy on disease control and survival outcome in metastatic colorectal cancer patients.
143 Background: Colorectal liver metastasis (LM) presents a therapeutic challenge in tailoring optimal treatment for patie...
Distribution of driver and allele-specific KRAS mutations across racial and ethnic groups in pancreatic adenocarcinoma.
773 Background: Pancreatic ductal adenocarcinoma (PDAC) arises from recurrent alterations in core driver genes, yet the in...
Phase I/Ib study of inavolisib (INAVO) + bevacizumab (BEV) or cetuximab (CETUX) for <i>PIK3CA</i> -mutated (mut) metastatic colorectal cancer (mCRC).
158 Background: PIK3CA mutations are common in CRC and may be a negative prognostic factor. INAVO is a...
An open-label, randomized, multicenter, phase 3 study of trastuzumab deruxtecan (T-DXd) + chemotherapy (chemo) ± pembrolizumab (pembro) versus chemo + trastuzumab ± pembro in first-line metastatic HER2+ gastric or gastroesophageal junction (GEJ) cancer: DESTINY-Gastric05.
TPS468 Background: An unmet medical need remains in patients (pts) with HER2+ gastric or GEJ cancer. HER2 is a validated t...
Evaluation of modified gemcitabine/nab-paclitaxel schedules in first line therapy for advanced pancreatic cancer: MI-OPTS-2 study.
734 Background: Gemcitabine/nab-paclitaxel (GnP), a standard first-line treatment option for advanced pancreatic cancer (a...
Differential efficacy of immunotherapy in hepatocellular carcinoma (HCC) based on etiology: A systematic review and meta-analysis in viral vs. non-viral HCC.
542 Background: The tumor immune microenvironment (TIME) of hepatocellular carcinoma (HCC) varies significantly by etiolog...
Clinical management of perioperative FLOT for resectable gastric, gastroesophageal junction, or esophageal adenocarcinoma: Practical insights from a Japanese single-institute experience.
341 Background: Perioperative FLOT (fluorouracil, leucovorin, oxaliplatin, and docetaxel) has been the standard of care fo...
A phase 1/2, randomized, global trial to investigate efficacy and safety of EpCAM × 4-1BB bsAb (BNT314/GEN1059) in combination with pumitamig (BNT327; PD-L1 × VEGF-A bsAb) and chemotherapy in patients with metastatic colorectal cancer (mCRC).
TPS266 Background: Pumitamig (BNT327, PD-L1 × VEGF-A bsAb) and BNT314 (GEN1059/DuoBody-EpCAM×4-1BB) are investigational bi...
Comparative outcomes of evolving vs conventional regimens in BRAF V600E-mutated metastatic colorectal cancer therapy: A systematic review.
175 Background: BRAF V600E mutations occur in ~8–12% of metastatic colorectal cancer (mCRC) and are linked to poor prognos...
Phase 1/2 study of ARV-806, a PROTAC KRAS G12D degrader, in <i>KRAS</i> G12D–mutated advanced solid tumors, including pancreatic cancer.
TPS792 Background: Mutated KRAS is a common oncogenic driver of pancreatic, colore...
Prognostic impact of HRD status and ARID1A expression in individual gastrointestinal cancers.
844 Background: Homologous recombination deficiency (HRD) scores quantify genomic instability based on chromosomal alterat...
Adebrelimab combined with albumin-paclitaxel and nedaplatin as neoadjuvant therapy for locally advanced resectable esophageal squamous cell carcinoma: A multicenter, single-arm, phase II clinical study.
410 Background: Adebrelimab is a high-affinity humanized anti-PD-L1 monoclonal antibody that has shown efficacy and a favo...